Market Currents
Credit Suisse thinks investors are overlooking the potential of Merck's (MRK -1%) PH III...
-
Monday, June 25, 2012, 3:14 PM ETCredit Suisse thinks investors are overlooking the potential of Merck's (MRK -1%) PH III osteoporosis drug odanacatib. The firm says it expects increased focus on it with 2 interim efficacy reports expected this year, and raises its 2020 estimate for the drug to $1.1B from $350M.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
